• 作者：B. De Bari^a ; ^b ; ^{bdebari@yahoo.it} ; L. Lestrade^a ; ^b ; P.-J. Souquet^c ; Y. Pacheco^c ; L. Geriniere^c ; B. Guibert^d ; F. Mornex^a ; ^b
• 关键词：Carcinome pulmonaire non à ; petites cellules ; Tumeur de Pancoast ; Chimioradiothé ; rapie ; Contrô ; le local ; Survie globale ; Toxicité
• 刊名：Cancer Radiotherapie
• 出版年：2012
• 期刊代码：45_12783218
• 类别：med
• 出版时间：April, 2012
• 卷：16
• 期：2
• 页码：107-114
• 文件大小：348 K

Purpose

Superior sulcus non-small cell lung cancer represents less than 5%of all lung cancers and is a challenge for the physicians because of clinical presentation, treatments related toxicities and poor prognosis. The aim of this preliminary retrospective report is to present outcomes of patients affected by a superior sulcus non-small cell lung cancer, treated by high dose radiotherapy (> 60 Gy) with or withour chemotherapy.

Patients and methods

All adult inoperable or unresectable patients (鈮?#xA0;18 years) with a clinical and radiological diagnosis of superior sulcus non-small cell lung cancer treated in our department by radiotherapy with or without chemotherapy were retrospectively analysed. Primary endpoint was the local control. Overall survival, metastasis free survival and toxicity rates were also analysed and reported.

Results

From January 1999 to June 2009, 12 patients were treated by exclusive high-dose radiochemotherapy. Median age was 53 years (range: 33-64 years); mean follow-up time was 20 months (range: 2-75 months). Mean local control, overall survival and metastasis free survival were 20.2, 22 and 20 months, respectively. At the time of this analysis, seven patients died of cancer and three of them presented only a metastatic disease progression. One patient died of acute cardiac failure 36 months after the end of radiochemotherapy and was disease free. Treatment was well tolerated and any acute and/or late G3-4 toxicity was recorded (NCI-CTC v 3.0 score).

Conclusion

This analysis confirms the interest of exclusive high-dose radiochemotherapy in treating inoperable superior sulcus non-small cell lung cancer patients, in achieving good local control and overall survival rates.